465 assets in Obesity Disorder

Therapeutic assets addressing Obesity Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Multiple Vitamins Injection Obesity Disorder	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	P2	CC (46)
Nabilone Obesity Disorder	Centre for Addiction and Mental Health	P2	CC (46)
Nimacimab Obesity Disorder	Skye Bioscience, Inc.	P2	CC (46)
nt-0796 Obesity Disorder	NodThera Limited	P2	CC (46)
Pegargiminase Obesity Disorder	Washington University School of Medicine	P2	CC (46)
Relebactam Obesity Disorder	University of Illinois at Chicago	P4	CC (46)
Ribupatide Obesity Disorder	Kailera	P2	CC (46)
Rifaldazine Obesity Disorder	Vincentage Pharma Co., Ltd	P1	CC (46)
(S)-(-)-Pindolol Benzoate Obesity Disorder	Actimed Therapeutics Ltd	P2	CC (46)
Sucralose Obesity Disorder	Virginia Polytechnic Institute and State University	P2	CC (46)
Taldefgrobep Alfa Obesity Disorder	Biohaven Therapeutics Ltd.	P2	CC (46)
Trevogrumab Obesity Disorder	Regeneron Pharmaceuticals	P2	CC (46)
Vericiguat Obesity Disorder	University of Alabama at Birmingham	P2	CC (46)
Warfarin Obesity Disorder	Beijing QL Biopharmaceutical Co.,Ltd	P1	CC (46)
Celecoxib Obesity Disorder	ARKAY Therapeutics	P1/2	CC (45)
Deuterated Water Obesity Disorder	Columbia University	P1/2	CC (45)
Gly-Low Obesity Disorder	University of California, San Francisco	P1/2	CC (45)
ct-996 Obesity Disorder	Carmot Australia First Pty Ltd	P1	CC (44)
Exenatide [Bydureon] Obesity Disorder	Vivani Medical, Inc	P1	CC (44)
gma106 Obesity Disorder	Gmax Biopharm Australia Pty Ltd.	P1	CC (44)
Hrs-4729 Obesity Disorder	Fujian Shengdi Pharmaceutical Co., Ltd.	P1	CC (44)
hs235 Obesity Disorder	35Pharma Inc	P1	CC (44)
Hydrocortisone Obesity Disorder	Eleonora Seelig	P1	CC (44)
Mulberry Twig Alkaloids Tablets Obesity Disorder	Beijing Wehand-Bio Pharmaceutical Co., Ltd	P1	CC (44)
Ondansetron Obesity Disorder	IVO JURISIC	P1	CC (44)
Acetic Acid, Sodium Salt (1:1) Obesity Disorder	Columbia University	P1	CC (43)
Alpelisib Obesity Disorder	Columbia University	P1	CC (43)
bi 3034701 Obesity Disorder	Boehringer Ingelheim	P2	CC (43)
Crb-913 Obesity Disorder	Corbus Pharmaceuticals Inc.	P1	CC (43)
D-Thioctic Acid Obesity Disorder	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	P2	CC (43)
gs-4571 Obesity Disorder	Gilead Sciences	P1	CC (43)
Ibio-600 Obesity Disorder	iBio, Inc.	P1	CC (43)
lae103 Obesity Disorder	Laekna Limited	P1	CC (43)
Repaglinide Obesity Disorder	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	P1	CC (43)
SA030 Obesity Disorder	Suzhou Siran Biotechnology Co.,Ltd.	P1	CC (43)
VX-201 Obesity Disorder	Terrestrial Bio, Inc.	P1	CC (43)
bi 1820237 Obesity Disorder	Boehringer Ingelheim	P1	CC (42)
Ethinyl Estradiol Obesity Disorder	Amgen	P1	CC (42)
Iohexol Obesity Disorder	University of Colorado, Denver	P1/2	CC (42)
Itraconazole Obesity Disorder	Shionogi	P1	CC (42)
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R,R))- Obesity Disorder	Columbia University	P1	CC (42)
Lotiglipron Obesity Disorder	Pfizer	P2	CC (42)
Moxifloxacin Obesity Disorder	Amgen	P1	CC (42)
Omeprazole Obesity Disorder	Shandong Suncadia Medicine Co., Ltd.	P1	CC (42)
pb-119 Obesity Disorder	PegBio Co., Ltd.	P1/2	CC (42)
pb-718 Obesity Disorder	PegBio Co., Ltd.	P1/2	CC (42)
Sodium P-Aminohippurate Obesity Disorder	University of Colorado, Denver	P1/2	CC (42)
bgm1812 Obesity Disorder	BrightGene Bio-Medical Technology Co., Ltd.	P1	CC (41)
Dexasone Obesity Disorder	University of North Carolina, Chapel Hill	P1	CC (41)
DWC202502 Obesity Disorder	Daewoong Pharmaceutical Co. LTD.	P1	CC (41)

Showing 251 to 300 of 465 assets

PreviousPage 6 of 10Next